Trioar, a drug development company based in Daejeon, South Korea, specializes in creating drugs that overcome the limitations of existing antibody therapeutics and antibody-drug conjugates. Their drugs detect cancer lesions, allowing for quick absorption and precise targeting of cancer cells, ultimately leading to rapid cancer cell death. By providing effective solutions for patients, Trioar aims to contribute to the advancement of cancer treatment. Founded in 2021, Trioar focuses on biotechnological research and the manufacturing of pharmaceutical products and drugs.